source
- Amgen ends $500M Crohn’s disease collaboration with TScan, but TScan says pipeline strategy stays on trackAmgen has terminated its collaboration with TScan Therapeutics that was aimed at Crohn’s disease, ending a deal that could have delivered up to $500 million in milestones. The partnership began in…
- AstraZeneca’s Tagrisso plus Orpathys improves survival in MET-mutated lung cancerA new combination therapy using AstraZeneca’s Tagrisso together with Hutchmed’s Orpathys has shown a survival benefit for patients with a specific form of non‑small cell lung cancer. The study focu…